Publications by authors named "Qasim Rana Khan"
Background: Perianal fistula (PAF), a complication of Crohn's disease (CD), is associated with substantial economic costs and poor prognosis. We determined prevalence of PAF CD in the United States and compared costs and health care resource utilization (HRU) of PAF CD patients with matched non-PAF CD patients.
Methods: This was a retrospective cohort study of claims data from the IBM MarketScan Commercial Database from October 1, 2015, to September 30, 2018.
Article Synopsis
- Vedolizumab (ENTYVIO) is a medication used to treat inflammatory bowel disease by blocking specific immune cell trafficking to the gut, and it's important to evaluate the risk of opportunistic infections in patients taking it.
- In clinical trials and post-marketing data, the annual incidence of opportunistic infections was low, at approximately 0.7 to 1.0 per 100 patient-years, with Clostridium difficile being the most common.
- Interestingly, tuberculosis occurrences were rare, with no related deaths reported, and patients with histories of hepatitis B/C did not experience viral reactivation while on vedolizumab.